2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Weintraub D, Caspell‐Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M, Initiative P. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals Of Clinical And Translational Neurology 2020, 7: 449-461. PMID: 32285645, PMCID: PMC7187707, DOI: 10.1002/acn3.51022.Peer-Reviewed Original ResearchConceptsParkinson's disease participantsNeuropsychiatric symptomsParkinson's diseaseHealthy controlsCognitive impairmentMedication useYear 5Anticholinergic medication useCross-sectional prevalenceParkinson's disease patientsHypnotic useDisease patientsNeuropsychiatric featuresDisease onsetAnnual visitsSymptomsDisorder subtypesAbsolute prevalenceDiseaseTime pointsPrevalenceBaselineImpairmentParticipantsOnset
2018
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D, Initiative T. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLOS ONE 2018, 13: e0201964. PMID: 30125297, PMCID: PMC6101368, DOI: 10.1371/journal.pone.0201964.Peer-Reviewed Original ResearchConceptsParkinson's diseaseIdiopathic REM sleep behavior disorderParkinson's Progression Markers Initiative (PPMI) studyDe novo Parkinson's diseaseREM sleep behavior disorderDopamine transporterNon-motor symptomsNovo Parkinson's diseaseSleep behavior disorderNon-motor featuresSymbol Digit Modalities TestBaseline neuropsychological performanceMontreal Cognitive AssessmentFuture neurodegenerationLewy bodiesInclusion criteriaSpectrum of riskMutation carriersInitiative studyCohortBehavior disorderCognitive functionCognitive test scoresModalities TestNeuropsychological performance
2017
Cognition and the course of prodromal Parkinson's disease
Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition and the course of prodromal Parkinson's disease. Movement Disorders 2017, 32: 1640-1645. PMID: 29063713, PMCID: PMC5722226, DOI: 10.1002/mds.27189.Peer-Reviewed Original ResearchConceptsSpeed/attentionCognitive declineProdromal participantsBaseline neuropsychological test performanceExecutive function/Role of cognitionNeuropsychological test performanceFuture cognitive declineBaseline cognitive scoresCognitive domainsGlobal cognitionBaseline cognitionCognitive scoresCognitionTest performanceFuture declinePD-convertersDopamine systemHyposmic individualsProdromal PDLongitudinal changesFunction/ParticipantsDopamine transporter bindingIndividualsMultiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, Initiative T. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLOS ONE 2017, 12: e0175674. PMID: 28520803, PMCID: PMC5435130, DOI: 10.1371/journal.pone.0175674.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCognitive DysfunctionDiffusion Tensor ImagingDopamine Plasma Membrane Transport ProteinsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedParkinson DiseasePolymorphism, Single NucleotideTau ProteinsTomography, Emission-Computed, Single-PhotonConceptsParkinson's diseaseCognitive impairmentDe novo Parkinson's diseaseDopamine transporter single-photon emissionLongitudinal mixed-effects modelsNovo Parkinson's diseaseYears of diseaseIdiopathic Parkinson's diseaseMovement Disorders CenterSingle nucleotide polymorphismsStructural magnetic resonance imagingClinical trial designLongitudinal structural MRIMagnetic resonance imagingSingle photon emissionDevelopment of treatmentsDiffusion tensor imagingBiomarker predictorsPlaque pathologyAmyloid pathologyDopamine deficiencyDopaminergic deficitUnivariate analysisBiomarker changesDisorders Center
2015
Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings
Chahine M, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Movement Disorders 2015, 31: 86-94. PMID: 26293177, PMCID: PMC4827252, DOI: 10.1002/mds.26373.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnxietyAttentionCocaineCognition DisordersCohort StudiesExecutive FunctionFemaleHumansLanguageMaleMemoryMiddle AgedNeurogenic BowelNeuropsychological TestsOlfaction DisordersParkinson DiseaseProtein BindingRadiopharmaceuticalsSelf ReportSeverity of Illness IndexStatistics, NonparametricSurveys and QuestionnairesTomography, Emission-Computed, Single-PhotonVisual PerceptionConceptsExecutive function/Global cognitionRelative impairmentSpecific cognitive domainsSpeed/attentionGlobal cognitive abilityNeuropsychological test batteryLower global cognitionFunction/Cognitive abilitiesCognitive domainsCognitive profileVisuospatial abilitiesLanguage domainsCognitive testingTest batteryCognitionNormative scoresMemoryLower mean scoresHealthy adultsNon-motor featuresIndividualsStudy findingsNon-motor symptomsCognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors
2012
Traditional neuropsychological correlates and reliability of the Automated Neuropsychological Assessment Metrics-4 battery for Parkinson’s disease
Hawkins KA, Jennings D, Vincent AS, Gilliland K, West A, Marek K. Traditional neuropsychological correlates and reliability of the Automated Neuropsychological Assessment Metrics-4 battery for Parkinson’s disease. Parkinsonism & Related Disorders 2012, 18: 864-870. PMID: 22609082, DOI: 10.1016/j.parkreldis.2012.04.021.Peer-Reviewed Original ResearchImpaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study
Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K, Investigators T. Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study. Movement Disorders 2012, 27: 406-412. PMID: 22237833, PMCID: PMC6342466, DOI: 10.1002/mds.24892.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesConstipationFemaleHumansMaleMiddle AgedMood DisordersOlfaction DisordersParkinson DiseaseRisk FactorsConceptsNonmotor featuresProdromal featuresOlfactory testingRapid eye movement sleep behaviour disorder symptomsSyndrome StudyPennsylvania Smell Identification TestDopamine transporter imagingPercent of subjectsSmell Identification TestRisk of PDFuture neurodegenerationHyposmic subjectsOlfactory dysfunctionImpaired olfactionTransporter imagingMotor functionMotor featuresSmell testNeurological diagnosisUndiagnosed individualsHyposmiaScreening testSpecific markersDisorder symptomsFurther assessment
2011
The Parkinson Progression Marker Initiative (PPMI)
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Klinik P, Sherer T, Frasier M, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Zhang Y, Toga A, Crawford K, Ansbach A, De Blasio P, Piovella M, Trojanowski J, Shaw L, Singleton A, Hawkins K, Eberling J, Brooks D, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Delgado H, Jankovic J, Hunter C, Stern M, Tran B, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Lang E, Shill H, Obradov S, Fernandez H, Winters A, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, Gerstenhaber M, Brooks D, Malloy S, Barone P, Longo K, Comery T, Ravina B, Grachev I, Gallagher K, Collins M, Widnell K, Ostrowizki S, Fontoura P, Ho T, Luthman J, van der Brug M, Reith A, Taylor P, Initiative T. The Parkinson Progression Marker Initiative (PPMI). Progress In Neurobiology 2011, 95: 629-635. PMID: 21930184, PMCID: PMC9014725, DOI: 10.1016/j.pneurobio.2011.09.005.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeProgression Markers InitiativeProgression biomarkersCerebrospinal fluidMulti-center studyTherapeutic trialsPPMI cohortHealthy subjectsBiomarker assessmentClinical sitesStudy databaseReview CommitteeDisease etiologyLongitudinal collectionComprehensive observationalBiomarkersStudy dataAcquisition protocolsLikelihood of successEtiologyCohortBlood